{"DataElement":{"publicId":"7149522","version":"1","preferredName":"Hematologic Improvement-Erythroid Response Occurrence Type","preferredDefinition":"A description of the hematologic improvement erythroid response.","longName":"7149518v1.0:7149520v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7149518","version":"1","preferredName":"Hematologic Improvement-Erythroid Response Occurrence","preferredDefinition":"An improvement in erythrocyte count as a response to treatment._An instance of something happening, such as an event or incident.","longName":"7187777v1.0:2234856v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7187777","version":"1","preferredName":"Hematologic Improvement-Erythroid Response","preferredDefinition":"An improvement in erythrocyte count as a response to treatment.","longName":"C123585","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Erythroid Response","conceptCode":"C123585","definition":"An improvement in erythrocyte count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A00B7420-1EA8-4B94-E053-F662850ABAC4","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE51946-2DCB-2493-E053-F662850AE799","latestVersionIndicator":"Yes","beginDate":"2020-01-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-24","modifiedBy":"KUMMEROA","dateModified":"2020-10-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7149520","version":"1","preferredName":"Hematologic Improvement-Erythroid Response Type","preferredDefinition":"An improvement in erythrocyte count as a response to treatment._Something distinguishable as an identifiable class based on common qualities.","longName":"7149520v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Major response","valueDescription":"IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden","ValueMeaning":{"publicId":"7187774","version":"1","preferredName":"IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden","longName":"7187774","preferredDefinition":"Major hematologic improvement-erythroid response in high transfusion burden patients corresponds to transfusion independence, defined by the absence of any transfusions over a period of a minimum of 8 weeks within an observation period of 16 to 24 weeks with the same transfusion policy (defined in “1.2.4. Transfusion policy”) compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden","conceptCode":"C170520","definition":"Major hematologic improvement-erythroid response in high transfusion burden patients corresponds to transfusion independence, defined by the absence of any transfusions over a period of a minimum of 8 weeks within an observation period of 16 to 24 weeks with the same transfusion policy (defined in \"1.2.4. Transfusion policy\") compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A009923E-E59A-04F5-E053-F662850AE605","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A009923E-E5B5-04F5-E053-F662850AE605","beginDate":"2020-01-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","deletedIndicator":"No"},{"value":"Minor response","valueDescription":"IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden","ValueMeaning":{"publicId":"7187775","version":"1","preferredName":"IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden","longName":"7187775","preferredDefinition":"Minor hematologic improvement-erythroid response in high transfusion burden patients is defined as a reduction by at least 50% of RBCs over a minimum of 8 weeks with the same transfusion policy (defined in “1.2.4. Transfusion policy”) compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden","conceptCode":"C170521","definition":"Minor hematologic improvement-erythroid response in high transfusion burden patients is defined as a reduction by at least 50% of RBCs over a minimum of 8 weeks with the same transfusion policy (defined in \"1.2.4. Transfusion policy\") compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A009923E-E5C1-04F5-E053-F662850AE605","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A009923E-E5DC-04F5-E053-F662850AE605","beginDate":"2020-01-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7187771","version":"1","preferredName":"Hematologic Improvement-Erythroid Response Type","preferredDefinition":"An improvement in erythrocyte count as a response to treatment.:Something distinguishable as an identifiable class based on common qualities.","longName":"C123585:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Erythroid Response","conceptCode":"C123585","definition":"An improvement in erythrocyte count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A009923E-E502-04F5-E053-F662850AE605","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-04","modifiedBy":"ONEDATA","dateModified":"2020-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE64D68-F8DD-65DF-E053-F662850A5335","latestVersionIndicator":"Yes","beginDate":"2020-01-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-24","modifiedBy":"KUMMEROA","dateModified":"2020-10-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MDS_hema_imp_dis_resp","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the hematologic impr","type":"Preferred Question Text","description":"What was the hematologic improvement erythroid response?","url":null,"context":"NHLBI"},{"name":"Specify the response achieved","type":"Application Standard Question Text","description":"Specify the response achieved","url":null,"context":"NHLBI"},{"name":"Specify the response achieved","type":"Alternate Question Text","description":"Specify the response achieved","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE51946-2DE2-2493-E053-F662850AE799","latestVersionIndicator":"Yes","beginDate":"2020-01-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-24","modifiedBy":"KUMMEROA","dateModified":"2020-10-07","changeDescription":". System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}